Abstract: Adding a lubricant having a metal stearate and polytetrafluoroethylene (PTFE) to a downhole fluid may lubricate a first surface once the downhole fluid has been circulated within a subterranean reservoir wellbore. Friction, torque, and/or drag may be reduced when the lubricated first surface contacts a second surface. The first surface may be or include, but is not limited to a wellbore casing, a drill string, a pipe, a formation, a drill bit, a metal surface within a mud motor, formation evaluation tool, at least one drilling tool, and combinations thereof. One or both of the first and second surfaces may be metal. The downhole fluid may be or include, but is not limited to, a drilling fluid, a completion fluid, a fracturing fluid, a drill-in fluid, a workover fluid, and combinations thereof.

Abstract: Adding a lubricant having a metal stearate and polytetrafluoroethylene (PTFE) to a downhole fluid may lubricate a first surface once the downhole fluid has been circulated within a subterranean reservoir wellbore. Friction, torque, and/or drag may be reduced when the lubricated first surface contacts a second surface. The first surface may be or include, but is not limited to a wellbore casing, a drill string, a pipe, a formation, a drill bit, a metal surface within a mud motor, formation evaluation tool, at least one drilling tool, and combinations thereof. One or both of the first and second surfaces may be metal. The downhole fluid may be or include, but is not limited to, a drilling fluid, a completion fluid, a fracturing fluid, a drill-in fluid, a workover fluid, and combinations thereof.

Abstract: Lubricants and drilling fluid systems comprising lubricants which form a coherent lubricating film on metal equipment, thereby prolonging equipment life even under a wide variety of conditions, including high temperature and/or high pressure conditions.

Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehyd-ro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehyd-ro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: A process for assessing mitochondrial toxicity of a compound that includes contacting nucleic acids from a host with an amplification reaction mixture that contains at least two primers that provide detectable signals, wherein: a first primer provides a first detectable signal upon amplification of a host mitochondrial nucleic acid; a second primer provides a second detectable signal upon amplification of a host nuclear nucleic acid; and comparing the first and second detectable signals.

Abstract: Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents.

Abstract: A torsion damping mechanism for a rotary blower is provided that has improved durability and ease of installation into the rotary blower. A rotary blower including a torsion damping mechanism according to an embodiment of the present invention is also provided.

Abstract: Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents.

Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehydro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: A torsion damping mechanism for a rotary blower is provided that has improved durability and ease of installation into the rotary blower. A rotary blower including a torsion damping mechanism according to an embodiment of the present invention is also provided.

Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acyl-2?,3?-dideoxy-5-fluorocytidine or N4-acyl-2?,3?-didehydro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: The present invention includes compounds and compositions of ?-halonucleosides, as well as methods to treat HIV, HBV or abnormal cellular proliferation comprising administering said compounds or compositions.

Abstract: The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: The disclosed invention is a composition for and a method of treating Flaviviridae (Hepacivirus, Flavivirus, Pestivirus) infections, including BVDV and HCV, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.

Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acyl-2′,3′-dideoxy-5-fluorocytidine or N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: This invention relates to a method of treating human immunodeficiency virus (HIV) infection in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one cyclic HIV protease inhibitor and (ii) at least one HIV reverse transcriptase inhibitor.

Abstract: A torsion isolator assembly (30) for reducing driveline torsionals includes a vane damper (36) having valving (40d,40e) for regulating the damping factor of the damper, spiral springs (32,34 or 82,84), and cam surfaces (44d,44c) which engage the ends of the spiral springs (32,34 or 82,84).; The spiral springs (32,34 or 82,84) have a lesser radial spacing between the outer convolutions as compared to the radial spacing between the inner convolutions.

Abstract: The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.